A new COVID-19 variant designated BA.3.2, nicknamed the ‘Cicada’ variant, has emerged as an Omicron descendant carrying more than 50 spike protein mutations. Despite this unusually high number of genetic changes, early observations indicate it is circulating at low to moderate levels without overtaking dominant strains.


According to the World Health Organization analysis, BA.3.2 carries over 70 total genetic changes compared to the original SARS-CoV-2 strain. The variant likely evolved from the BA.3 lineage and may have developed undetected for months, possibly in a chronically infected individual, a phenomenon known as a saltation event. The ‘Cicada’ nickname reflects this hidden evolution before detection.


The variant has been identified across multiple regions, including South Africa, Europe, the United States, and Australia. However, Centers for Disease Control and Prevention surveillance data show it remains at low prevalence, typically representing only a small fraction of sequenced cases. It is currently classified as a Variant Under Monitoring.


Symptom patterns appear similar to recent Omicron descendants, with mostly mild respiratory effects including fatigue, sore throat, cough, and mild respiratory discomfort. There is no evidence linking BA.3.2 to higher hospitalisation rates or increased mortality compared to other circulating strains.


Laboratory findings suggest the variant may partially reduce antibody neutralisation from prior infection or vaccination, though this pattern is common among Omicron descendants. According to Johns Hopkins Medicine, vaccines continue to provide strong protection against serious outcomes, including hospitalisation and death.


Health authorities continue monitoring through genomic sequencing and wastewater analysis to track any changes in the variant’s behaviour.


Source: Nature World News / WHO, CDC, Johns Hopkins Medicine (2026)